Last Updated: May 20, 2026

Claims for Patent: 11,084,880

✉ Email this page to a colleague

Summary for Patent: 11,084,880

Title:	Anti-BCMA chimeric antigen receptor
Abstract:	The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
Inventor(s):	Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
Assignee:	Novartis AG , University of Pennsylvania Penn
Application Number:	US16/197,565

Details for Patent 11,084,880

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	December 23, 2013	⤷ Start Trial	2038-11-21
Kite Pharma Inc.	TECARTUS	brexucabtagene autoleucel	For Injection	125703	July 24, 2020	⤷ Start Trial	2038-11-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,084,880

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016014565	⤷ Start Trial
United States of America	2022064316	⤷ Start Trial
United States of America	2019153061	⤷ Start Trial
United States of America	2016046724	⤷ Start Trial
United States of America	12214037	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.